基本信息
浏览量:769
职业迁徙
个人简介
I am a medical oncologist with more than 20 years of experience in treating patients with a broad spectrum of head and neck malignancies including tumors of the mouth, throat, thyroid, salivary glands, and skin. For these years of service, I was honored to receive Memorial Sloan Kettering’s Willet F. Whitmore Award for Clinical Excellence in 2011.
Read more
As Chief of the Head and Neck Oncology Service and Co-Leader of our multidisciplinary disease management team, I work closely with an esteemed and highly coordinated group of medical oncologists, surgeons, radiation oncologists, nurses, and other healthcare professionals to provide our patients with the very best care possible.
Collaborative, multidisciplinary care is especially important for cancers of the head and neck because, generally speaking, treatment not only involves a potentially deadly disease but also issues related to physical appearance, function, and quality of life. An approach that I pioneered with Memorial Sloan Kettering colleagues — known as combined modality organ preservation therapy — uses a combination of chemotherapy and radiation to avoid certain surgical procedures feared by patients such as removal of the voice box, with the intent of preserving function and cosmetic appearance without compromising survival.
My current research is focused on evaluating new forms of chemotherapy called targeted therapies, which selectively kill cancer cells while leaving healthy cells alone. I am also developing customized combined modality therapies based on prognostic risk, and assessing healthcare outcomes.
I have published extensively, previously serving as an associate editor for Clinical Cancer Research and on the editorial board of the Journal of Clinical Oncology, and have been principal investigator on multiple studies.
In addition to being a member of the board of directors for the National Comprehensive Cancer Network, I chair the organization’s head and neck cancer practice guidelines panel. I am also on the board of directors for the International Thyroid Oncology Group, and am co-chair of the Head and Neck Cancer Recurrent/Metastatic Disease Task Force at the National Cancer Institute. Here at Memorial Sloan Kettering, I chair the Committee on Metrics of Care Quality and Outcome.
Awards and Honors
Castle Connolly: New York Magazine Top Doctors (2005-2008, 2010-2018)
Read more
As Chief of the Head and Neck Oncology Service and Co-Leader of our multidisciplinary disease management team, I work closely with an esteemed and highly coordinated group of medical oncologists, surgeons, radiation oncologists, nurses, and other healthcare professionals to provide our patients with the very best care possible.
Collaborative, multidisciplinary care is especially important for cancers of the head and neck because, generally speaking, treatment not only involves a potentially deadly disease but also issues related to physical appearance, function, and quality of life. An approach that I pioneered with Memorial Sloan Kettering colleagues — known as combined modality organ preservation therapy — uses a combination of chemotherapy and radiation to avoid certain surgical procedures feared by patients such as removal of the voice box, with the intent of preserving function and cosmetic appearance without compromising survival.
My current research is focused on evaluating new forms of chemotherapy called targeted therapies, which selectively kill cancer cells while leaving healthy cells alone. I am also developing customized combined modality therapies based on prognostic risk, and assessing healthcare outcomes.
I have published extensively, previously serving as an associate editor for Clinical Cancer Research and on the editorial board of the Journal of Clinical Oncology, and have been principal investigator on multiple studies.
In addition to being a member of the board of directors for the National Comprehensive Cancer Network, I chair the organization’s head and neck cancer practice guidelines panel. I am also on the board of directors for the International Thyroid Oncology Group, and am co-chair of the Head and Neck Cancer Recurrent/Metastatic Disease Task Force at the National Cancer Institute. Here at Memorial Sloan Kettering, I chair the Committee on Metrics of Care Quality and Outcome.
Awards and Honors
Castle Connolly: New York Magazine Top Doctors (2005-2008, 2010-2018)
研究兴趣
论文共 342 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nancy Y Lee,Eric J Sherman,HeiKo Schöder,Rick Wray, Jay O Boyle,Bhuvanesh Singh,Milan Grkovski,Ramesh Paudyal, Louise Cunningham,Zhigang Zhang,Vaios Hatzoglou,Nora Katabi,
CANCERno. 5 (2024): 702-712
Maliheh Mohamadpour,Eric Jeffrey Sherman,Anuja Kriplani,James Vincent Fetten,Lara Dunn,Loren S. Michel,Kin Wai (Tony) Hung,Shrujal S. Baxi, Erin McDonald, Rachel Conybeare,Nora Katabi,Irina Ostrovnaya,
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 6048-6048
引用2浏览0引用
2
0
Antoine Desilets,Winston Wong,Gnana P. Krishnamoorthy,Eric Jeffrey Sherman,Lara Dunn,Anuja Kriplani,James Vincent Fetten,Loren S. Michel, Erin McDonald, Ravinder K. Grewal,Mona Sabra,Laura Boucai,
CLINICAL CANCER RESEARCHno. 18 (2023)
引用0浏览0引用
0
0
JAMA network openno. 6 (2023): e2316094-e2316094
引用0浏览0引用
0
0
Targeted oncology (2023)
引用0浏览0WOS引用
0
0
NATURE MEDICINEno. 12 (2023): 3077-3089
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn